Αποτελέσματα Αναζήτησης
However, in the United States, doxorubicin/cyclophosphamide (AC) is favored over FEC despite no data comparing neoadjuvant AC-THP with AC-TH or TCHP. Here we report outcomes for patients with localized HER2+ breast cancer treated with pertuzumab-containing neoadjuvant regimens and AC-TH.
19 Ιουν 2024 · With a primary endpoint of 5-year iDFS, the investigators were able to demonstrate considerable improvements to iDFS for those on a trastuzumab-containing regimen (AC-TH or TCH).
6 Οκτ 2011 · The major safety issue that we observed was increased cardiac dysfunction when trastuzumab was used in combination with anthracycline-based chemotherapy, a finding that is also concordant...
31 Ιουλ 2017 · Trastuzumab (Herceptin, Roche/Genentech) in combination with chemotherapy remains the standard of care for the adjuvant treatment of HER2+ breast cancer, but there is still a question over which...
10 Ιουν 2021 · The addition of trastuzumab to chemotherapy dramatically improved the prognosis of early-stage human epidermal growth factor receptor 2 (HER2)–positive breast cancer. However, 15%-31% of patients s...
14 Δεκ 2023 · This topic review will cover the use of adjuvant HER2-directed therapy plus chemotherapy in patients with HER2-positive, early-stage breast cancer (stage I to III).
Conclusions: TC has become a common choice for adjuvant chemotherapy among older patients. In all patients, 5-year OS was similar between groups, but OS may be higher for patients with stage III disease receiving ACT.
